Corporate

Investors Partnership IP

Partners

Intradigm is leveraging all three proprietary elements of its RNAi Nanoplex (NPX) delivery technology to pursue a partnership strategy designed to maximize corporate and shareholder value.  Partnering with Intradigm creates access to:

• Proprietary next-generation siRNA structures
• Proprietary and potent siRNA sequences
• Novel, systemic biodegradable delivery technology 

The goal of the company’s partnership strategy is the establishment of alliances with pharmaceutical and biotechnology companies for the development and advancement of specific RNAi therapeutics.  This will allow for the expansion of Intradigm’s proprietary RNAi NPX delivery technology to provide systemic targeted delivery against a broad spectrum of targets and therapeutic opportunities.   

Partnerships

To date, Intradigm has established several collaborations and licensing relationships with academic and industry partners including:

• Novartis Pharma
• Carnegie Institute
• M.I.T.
• MGH
• University of Massachusetts Medical School
• Stanford University
• Burnham Institute
• University of Maryland, Baltimore (UMB)
• Opko Corporation, formerly Acuity Pharmaceuticals

For collaboration/partnership inquiries please e-mail: phaworth@intradigm.com.